Purpose: Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for responsive versus nonresponsive tumors.
Introduction
Lapatinib is a tyrosine kinase inhibitor (TKI) of both the epidermal growth factor receptor (EGFR, HER1) and human epidermal growth factor receptor-2 (HER2), which is an FDAapproved and commonly used drug in patients with HER2-positive (HER2 þ ) breast cancer (1) (2) (3) . Targeting this drug to the most appropriate subset of breast cancer patients depends on a full understanding of the molecular determinants of response. Although HER2 overexpression [3þ by immunohistochemistry (IHC)] or amplification is an important predictor of response to lapatinib, it may not be the only requirement. EGFR (HER1) protein expression by IHC has not been shown to correlate with response to lapatinib (4) , whereas the sensitizing EGFR gene mutations described in other tumor types (5) have not been reported in breast cancer. Either moderate levels of HER2 expression in the absence of gene amplification, the expression of other HER partners (i.e., EGFR, HER3), elevated levels of HER ligands, or activation of downstream effectors such as AKT and ERK could all be relevant to lapatinib responsiveness in breast cancer. As such, these additional biomarkers potentially could identify a subset of HER2 À nonamplified tumors that might respond to an EGFR/HER2 TKI. Changes in the marker of cell proliferation as determined by Ki67 following 2 weeks of treatment have been shown to predict recurrence-free survival in groups of patients with breast cancer treated with different hormonal agents (6, 7) . Assessment of in vivo surrogate markers, such as Ki67, associated with comprehensive molecular profiling may elucidate the differential profile of treatment-sensitive versus treatment-nonresponsive tumors (8) (9) (10) (11) . Ten to 14 days is the usual time interval between the diagnosis of breast cancer and primary surgery, offering a convenient window of opportunity for a short treatment with an experimental agent.
We therefore conducted a short-term presurgical study to determine the Molecular Antiproliferative Predictors of Lapatinib's Effects in breast cancer (MAPLE) to (i) determine whether lapatinib induces antiproliferative effects in both HER2 þ and HER2 À (i.e., nonamplified) breast cancer and (ii) identify biomarkers of sensitivity or nonresponsiveness to lapatinib. This was a multicenter presurgical double-blind study, designed to randomize 120 women with previously untreated primary breast cancer to lapatinib (1,500 mg/d; n ¼ 90) versus lapatinib-placebo (n ¼ 30) for 10 to 14 days between diagnosis and the day before surgery. Comprehensive molecular profiling of biopsies taken before treatment and at surgery was performed in an effort to identify predictors of sensitivity or nonresponsiveness to the antiproliferative effects of lapatinib. The primary objective was change in Ki67 after 2 weeks of therapy. Treatment-induced changes in apoptosis were also measured. These in vivo markers of drug effect (Ki67 and apoptosis) were correlated to baseline and treatment-induced changes in candidate molecular biomarkers.
Materials and Methods

Patients and samples
Women younger than 80 years presenting with newly diagnosed breast cancer scheduled for primary surgery were eligible. Other eligibility criteria included normal findings on screening cardiac examination, tumor tissue available for research, and at least 10 days' interval between randomization and the date of surgery. No concurrent or recent (within the last 28 days) hormonal therapy was allowed. Relevant demographics, medical history, physical examination, full blood count, and biochemistry were obtained at baseline, time of surgery, and at 1-month follow-up when the patient was discharged from the study. Toxicities were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Patients received lapatinib 1,500 mg orally once daily or placebo for 10 to 14 days until the day before surgery. Dose modifications and discontinuation were conducted as detailed in the protocol. Informed consent was obtained from all patients, and the study was approved by the South East England Main Research Ethics Committee (MREC) and the Medicine and Healthcare products Regulatory Agency (MHRA). The Institute of Cancer Research-Clinical Trials and Statistics Unit (ICR-CTSU) was responsible for the trial management of the study.
Patients were recruited from 10 sites in the United Kingdom. Patients were randomized in a 3:1 ratio to receive either lapatinib (N ¼ 90) or lapatinib-placebo (N ¼ 30) to complete 2 weeks of presurgical treatment. Randomization was performed with the use of computer-generated random permuted blocks stratified according to center. Randomization was performed via a telephone call to the ICR-CTSU and the treatment allocation was unknown to the patient; investigators and GlaxoSmithKline personnel were blinded to treatment allocation.
Up to two core-cut 14-gauge biopsies were obtained at both diagnosis and surgery. In some cases, only sections of the full excision specimen were available. The first core biopsy was placed immediately in formalin and fixed for 24 to 48 hours before processing to paraffin. The second optional core biopsy was incubated in RNA later at 4 C overnight before freezing at À20 C.
IHC and in situ hybridization IHC was performed as previously described (12) on 4-mm sections from paraffin-embedded blocks with the following antibodies: Ki67 (MIB-1), HER2 (Herceptest) from Dako, ERa (6F11) and PgR from VECTOR labs, stathmin, pAKT (Ser473), and pERK (Tyr202/Tyr204) from Cell Signaling Technology, and EGFR from Zymed. In addition, HER2 gene amplification was assessed in all cases by FISH using the Vysis method (Abott Molecular Inc.). For apoptosis, the terminal deoxynucleotidyltransferase-mediated UTP end-labeling (TUNEL) method was used.
All scoring was performed on paired samples by two experienced technicians blinded to treatment allocation. The percentages of Ki67-and TUNEL-positive cells were scored among 1,000 and 3,000 malignant cells, respectively. HER2 IHC and HER2 FISH were scored as per 2007 American Society of Clinical Oncology (ASCO) guidelines (13) . All cases were assessed by FISH as well, regardless of the IHC score. EGFR was scored using intensity (levels 1-3) and percentage positivity: strong was defined as >20% cells staining level 3, weak anything less, and negative as no staining. Nuclear staining for ER, PgR, pAKT, and pERK was done by H score, as previously published, resulting in a score between 0 and 300 (12) . ER and PgR positivity was defined by an H score of >1. Cytoplasmic scoring for stathmin, pAKT, and pERK was quantified by quickscore as previously validated (14) and results in a score between 0 and 18.
Real-time PCR
When sufficient material was available, RNA was extracted from two 10-mm sections of FFPE samples using the RecoverAll (Ambion) kit, cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen), and Taqman Gene Expression assays (PE Applied Biosystems) were used to measure RNA expression of HER2, HER3, NRG1, EREG, AREG, ESR1, EGFR, and three housekeeping genes (MRPL19, TBP, and TFRC). The results obtained were converted into relative concentrations using an in-run standard curve, and the observed relative concentrations were normalized to the mean of the three housekeeping genes.
Translational Relevance
The presurgical trial design offers a useful translational tool to investigate the in vivo antitumor effects of a novel agent by comparing biopsies obtained at diagnosis and at surgery after 2 weeks of treatment. In this case, we investigated, in a placebocontrolled trial, the effect of the HER1/2 tyrosine kinase inhibitor lapatinib on proliferation (Ki67) of primary breast cancers. The MAPLE presurgical trial demonstrated that the effects of lapatinib were not limited to HER2-amplified breast cancer, with a significant decrease in Ki67 in the HER2 nonamplified subset. Among HER2 À tumors, high HER3 mRNA identified Ki67 responders, and there was a trend for combined increase in HER3 and HER2 to predict response. Whether high levels of HER2-HER3 heterodimers may identify HER2 À patients who could benefit from lapatinib treatment merits further investigation.
Statistical considerations
Enrollment of 120 patients was required to demonstrate an overall decrease in Ki67 of 50% after 2 weeks of treatment. A 50% decrease in Ki67 with a standard error of 1.07 would imply a standardized difference of 0.65; therefore, 90 patients would give a power of more than 99% (two-sided P value, 0.0027) using a one-sample t test. A control group of 30 patients was required to obtain a sufficiently robust difference for the primary endpoint.
An interim analysis to examine safety and futility was planned for when 60 patients were evaluable for Ki67. At this point, emerging trial data were reviewed by the independent data monitoring committee, which could consider recommending early stopping of the trial if there was clear evidence that either treatment regimen was contraindicated (statistical significance level of P < 0.001).
The primary aim of this study was to determine the 2-week change in Ki67 in response to lapatinib treatment. The secondary objectives were (i) to investigate the relationship between changes in Ki67 and molecular markers at baseline, (ii) to investigate change in apoptosis, and if this was found to occur, examine its relationship to baseline biomarkers. The Wilcoxon signed-rank matched pairs test was used to compare expression levels in paired pre-and posttreatment samples, and the Spearman rank correlation was used to assess the relationship between change in Ki67 and baseline biomarker values and, more generally, correlation between two continuous factors. To examine whether baseline molecular markers predicted a greater than 50% Ki67 reduction in Ki67, logistic regression was also used, multivariable analysis being used to assess the simultaneous effect of several factors. Differences between means were compared using the MannWhitney test. All statistical tests were two tailed. Geometric means were used as the summary measure because many biomarkers demonstrated a distribution that is approximately log normal; to avoid taking the log of zero, a small negligible quantity was added to biomarker values, e.g., 0.1 was added to Ki67 percentage values. Statistical analyses were performed using Microsoft Excel 2010 and Stata 11.2 for Windows. For secondary analyses, a false discovery rate (FDR) of 5% was applied to 119 analyses that examined the ability of biomarkers to predict a decrease in Ki67 in lapatinib-treated patients; this gave a critical P value of 0.0008.
Results
Patients and treatment
A total of 121 patients were randomized over a 3-year period from 2008 until the accrual target was reached in 2011, and included in the toxicity analysis (Fig. 1) . The clinicopathologic characteristics were representative of an unselected patient population with early breast cancer and were balanced between the treatment groups ( Table 1) . The majority of patients were peri/ postmenopausal (57%), with a median tumor size of 23 mm, 46% were grade 3, and 81% were ER þ . Twenty-one percent (26 of 121) of patients had centrally confirmed HER2 þ breast cancer and included 25 HER2 3 þ tumors and one HER2 2 þ and FISH þ tumor.
All HER2 3 þ were also found to be FISH þ . The proportion of HER2 þ breast cancer (21%) was slightly higher than the 15%
expected from a population with early breast cancer, and may reflect the fact that trial entry required a palpable tumor, which may bias toward younger women with self-detected cancers over older women with screen-detected tumors; 26% of patients demonstrated detectable EGFR expression. Two weeks of lapatinib treatment was well tolerated and never resulted in any delay to scheduled surgery. The only toxicities that were significantly increased in the lapatinib versus placebo group were the occurrence of a rash (grade 3 rash was 6% vs. 0%; grade 1-2 rash was 64% vs. 12%; P < 0.001) and grade 1-2 diarrhea (56% vs. 8%; P ¼ 0.001; Supplementary Table S1 ). The only other grade 3 toxicity was infection in 1 patient.
Sample collection and baseline Ki67
Paired pre-and posttreatment samples containing sufficient tumor cells for analysis were collected in 98% (118 of 121) of randomized patients. In the case of 3 patients, the posttreatment sample contained no viable cancer cells, and all three tumors were HER2 þ from patients randomized to lapatinib. Therefore, 118
patients were included in the biomarker analyses (lapatinib, n ¼ 91, or placebo, n ¼ 27), and 100% (118 of 118) paired samples were of sufficient quality and cellularity (>1,000 tumor cells visualized) for analysis of the primary endpoint, Ki67. Of 118 patients available for primary endpoint analysis, three tumors were too small to allow more than two sections. Ki67 and HER2 staining was therefore available on 118 cases, while comprehensive IHC profiling was conducted on 115. The protocol requested that surgeons obtain posttreatment samples as core biopsies in the operating room and that they be fixed immediately, because extreme loss of staining of pAKT and pERK can occur during routine fixation of resection specimens (12) . In 72 of 118 (61%) cases, surgeons were able to obtain core-needle biopsies (CNB) at the time of surgery; for the remaining 46 cases, the posttreatment sample was a block cut from the surgical excision specimen (ES) in pathology. Analyses of pERK and pAKT were confined to CNB samples. In terms of the baseline proliferation levels in the tumor, as expected, Ki67 levels were significantly higher among ER À versus Fig. S1 ). In absolute terms, the difference in baseline Ki67 levels between HER2 þ and HER2 À tumors was quite small, even though it was significant at the P < 0.05 level (mean Ki67 ¼ 31% versus 20% for HER2 þ versus HER2 À tumors, respectively).
Change in Ki67 and apoptosis following 2 weeks of lapatinib In the lapatinib-treated group as a whole (n ¼ 91), there was a significant 31% reduction in Ki67 (95% CI, À43.6% to À16.3%). Importantly, there was no significant Ki67 change in the placebo group (À2.8%; 95% CI, À16.3% to þ13%). Although the Ki67 reduction was greatest among the lapatinib-treated HER2 þ subset (n ¼ 19) with a 46% reduction (95% CI, À62.6% to À23%; Fig.  2A) , there was also a significant 27% reduction in Ki67 among the HER2 À lapatinib-treated tumors (n ¼ 72; 95% CI, À41.9% to À7.6%; Fig. 2A and Table 2 ). Within this group, the proportion of Ki67 responders was higher among HER2 mRNA and HER3 mRNA-high patients (both above median) than among HER2 mRNA or HER3 mRNA-low (either below median): 6 of 22 (27%) versus 1 of 43 (2%; Supplementary Fig. S2 ).
As shown in Fig. 2B , the individual paired Ki67 changes show significant interpatient variability. Defining Ki67 responders or nonresponders as cases showing a >50% or <50% decrease in Ki67, respectively, there was a greater proportion of Ki67 responders (yellow lines in Fig. 2B ) among the HER2 þ subset (7 of 19; 37%); however, 14% (10 of 72) of HER2 À tumors demonstrated >50% reduction in Ki67 (Fig. 2B) .
As shown in the waterfall plots for individual tumor responses ( Fig. 3A and B) , some of the tumors demonstrating the greatest decrease in Ki67 were neither HER2 þ nor EGFR þ . There was no significant change in apoptosis with lapatinib in either HER2 þ or HER2 À tumors (Table 2 ).
Biomarker changes with 2 weeks of lapatinib As shown in Table 2 , there were no significant changes in EGFR or HER2 protein expression with lapatinib treatment. The effect of lapatinib on signaling downstream from those receptors was examined by measuring changes in pAKT and pERK by IHC (nuclear and cytoplasmic staining). Given the artifactual loss of phosphorylated proteins in excision versus core biopsies (12) , only paired samples containing a posttreatment core biopsy were included in the analyses of pAKT and pERK changes (n ¼ 57). Phosphorylated ERK was significantly downregulated with lapatinib treatment; in particular, nuclear pERK was reduced by 25% (P ¼ 0.008) in HER2 À cases (Table 2) . A significant reduction in cytoplasmic pAKT was observed in the HER2 þ subset (47% reduction; P ¼ 0.044). Stathmin has been suggested as a surrogate marker of PI3K-AKT pathway activation in gene expression assays that can be reproducibly measured by IHC (15) . Stathmin was significantly reduced by 23% and 25% in HER2 þ and HER2 À lapatinib-treated tumors (P ¼ 0.014 and P < 0.001, respectively; Table 2 ). There was no significant change in pERK, pAKT, or stathmin expression in paired placebo-treated cases (Supplementary Table S2 ); some reductions were observed, for example, stathmin was downregulated by 25% in the placebo group, a reduction similar to the lapatinib group. However, the numbers were small and the 95% CI too wide to be significant. In contrast, although there was a statistically significant 15% reduction in ER expression among HER2 À lapatinib-treated cases, it was not considered relevant, as a similar trend was observed with placebo (Supplementary Table S2 ). Changes in gene expression levels (mRNA) of EGFR and HER2 and ErbB ligands (neuregulin, amphiregulin, and epiregulin) were measured. Amphiregulin expression was significantly upregulated (P ¼ 0.02) with lapatinib treatment in the HER2 À subset only (Table 2 ), but not with placebo treatment, although the magnitude of the effect seen with placebo was similar but did not reach statistical significance due to the small numbers in this group (Supplementary Table S2 ). , a multivariable analysis was undertaken, testing baseline molecular markers for their ability to identify Ki67 responders (!50% Ki67 decrease) in HER2 À nonamplified tumors. Five baseline pretreatment parameters were significant at P < 0.05 and were considered in the analysis, namely protein expression of ER, PgR, pERK (cytoplasmic), and RNA expression levels of HER2, and of HER3 (Supplementary Table  S3 ). The analysis showed that only HER3 mRNA levels were independently significant, and HER2 lost significance once HER3 levels were allowed for. Moreover, there was a highly significant correlation between HER2 and HER3 mRNA expression (rho ¼ þ0.67, P < 0.001) in the HER2 À nonamplified tumors (Fig. 4) , and responders demonstrated high expression levels (above the median) for both HER2 and HER3 mRNA. The only biomarker change between baseline and 2 weeks that was significantly associated with Ki67 reduction was stathmin (rho ¼ þ0.44, P ¼ 0.001; Supplementary 
Discussion
There is a need for novel trial designs more specifically adapted to the molecular era of targeted cancer medicine. Conventional adjuvant trials in early breast cancer with large numbers of unselected patients and traditional clinical endpoints, such as progression-free survival (PFS) or overall survival (OS), require large numbers, with prolonged follow-up, and may not be appropriate for taking forward targeted therapies aimed at increasingly small subsets of patients. Presurgical trials using surrogate markers of in vivo drug activity, such as the cell proliferation marker Ki67, have emerged as a useful setting in which to investigate biologic predictors of response (9) . In addition, because such short-term (10-14 days) treatment exposure is of no proven clinical efficacy and study participation does not extend normal waiting time to surgery, an unselected patient population can be enrolled quickly in this clinical setting in an attempt to establish which tumors may exhibit the desired antiproliferative response. Furthermore, the randomization to a placebo is both permissible and acts as a valuable control for the biologic efficacy observed with the experimental therapy.
In the MAPLE study, we have confirmed that a short-term presurgical trial design in early breast cancer using an EGFR/HER2 TKI with a primary biologic antiproliferative endpoint is both feasible and safe, and that patients are willing to contribute sequential research biopsies. Our target patient recruitment was achieved in a reasonable time frame, with paired samples of adequate quality and cellularity obtained in 98% of patients. Because the primary endpoint was change in Ki67 and biomarker assessments were conducted as soon as paired samples were received, results were available shortly after recruitment was completed, thus illustrating how the presurgical trial design can provide a valuable tool to screen new agents in a fast and costeffective manner.
Short-term lapatinib treatment was associated with a significant Ki67 downregulation. Importantly, there was no evidence of a change in Ki67 in the placebo control group, indicating that no protocol-related interventions affected the primary endpoint. The trial included 26 patients with a HER2 þ tumor; 25 were HER2 3þ
by IHC and were found to also demonstrate HER2 amplification by FISH. The only patient with a HER2 2þ/FISH þ tumor was randomized to placebo. Although Ki67 reduction was greatest among HER2 þ tumors ( Fig. 2A) , lapatinib also resulted in a statistically significant 27% Ki67 downregulation among HER2 À nonamplified tumors. Although lapatinib is currently used exclusively in HER2 þ disease, MAPLE has shown that lapatinib may also have antiproliferative activity in a subset of HER2 À (Fig. 2B) , there was marked interpatient variability in Ki67 change, with 14% of HER2 À nonamplified lapatinib-treated tumors showing a >50% reduction in Ki67. We therefore investigated whether baseline biomarkers could identify these "Ki67 responders" (i.e., with a >50% Ki67 decrease), and demonstrated that among HER2 À tumors, the only independently significant baseline predictor for Ki67 response in a multivariable analysis was elevated levels of HER3 mRNA. These data are consistent with a recently reported smaller non-placebo-controlled study in 31 patients with HER2 À primary breast cancer where a similar >50% decrease in Ki67 was reported in four (14%) tumors, all of which expressed HER3 (16) . There has already been some evidence to suggest that HER2 inhibition may have a role in HER2-low breast cancer. Roughly 10% of patients enrolled in a trial of adjuvant chemotherapy alone or with trastuzumab revealed that some of the randomized patients were in fact neither HER2 3þ nor FISH amplified (17) . These HER2 À patients enrolled in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial had significantly better disease-free survival with a relative risk of 0.40 (P ¼ 0.026) when given trastuzumab after completing treatment for early breast cancer. These findings have provided the rationale for a large ongoing clinical trial, B-47. In addition, data from the Cancer and Leukemia Group B neoadjuvant study investigating the benefit of dual HER2 targeting suggest that intrinsic subtype is a strong driver of response to HER2-targeted therapy. Therefore, although HER2 overexpression or amplification may be an important predictor of response to HER2 targeted therapies, it may not be an obligate predictor (18) . In addition, there is a biologic rationale for expecting that in the setting of modest HER2 protein expression in nonamplified tumors, other molecular factors could determine an antiproliferative response to an intracellular TKI, such as levels of other HER family receptors that may heterodimerize with HER2 or levels of HER family ligands (19, 20) . HER2 activation requires receptor dimerization; HER2 has no known ligand, and activation occurs either via ligand-independent HER2 homodimerization associated with high levels of receptor membrane expression such as that found in HER2 gene-amplified tumors or, alternatively, via ligand-dependent receptor heterodimerization (i.e., EGFR: HER2, or HER2:HER3; ref. 21) . In contrast with the antibody trastuzumab that recognizes an epitope on the extracellular domain that is only exposed in the case of HER2 homodimers (21, 22) , the TKI lapatinib inhibits the intracellular domains of EGFR and HER2, and as such may also target various HER2-containing heterodimers. HER3 has a docking site for the p85 subunit of PI3K and acts as the preferred heterodimerization partner for HER2. HER2-HER3 heterodimers are increasingly identified as key drivers of the PI3K cell survival pathway (23) (24) (25) (26) . Activation of HER3 and downstream PI3K has been shown to predict resistance to trastuzumab but sensitivity to lapatinib in vitro (27) . In MAPLE, we have demonstrated that the HER2 À nonamplified tumors showing a Ki67 response with lapatinib tended to show elevated levels of both HER3 and HER2 (Fig. 4) , raising the possibility that a subset of HER2 À breast cancers with significant HER2:HER3 dimerization and activated PI3K signaling may be sensitive to the antiproliferative effects of lapatinib. Novel imaging technologies such as FRET/FLIM (F€ orster resonance energy transfer/fluorescence lifetime imaging) that can detect the physical association between these two proteins could be a useful technology to investigate the relevance of various HER family heterodimers and lapatinib responsiveness (28, 29) . Whereas phosphorylated HER3 and AKT are useful readouts of the PI3K pathway in vitro, pAKT and pHER3 have proven more challenging to detect in patient samples, and baseline pAKT did not predict response to lapatinib in MAPLE. The chromatinassociated protein stathmin has been identified as a surrogate measure of PI3K signaling (15) . In MAPLE, stathmin was significantly downregulated by lapatinib treatment in the HER2 À subset, whereas pAKT was not. However, a reduction in stathmin of similar magnitude was also observed in the placebo group, but was not statistically significant due to the small numbers in this group, indicating that further work is needed to confirm the effect of lapatinib on stathmin in the presurgical setting. More recent data indicate that stathmin is strongly related to proliferation, and this is likely to be detrimental to its use as a surrogate of PI3K signaling.
Not all HER2 þ patients benefit from lapatinib, and in MAPLE 
Disclosure of Potential Conflicts of Interest
